The MDS-16 was developed in 2016 by a worldwide team of researchers led by the prominent MD clinician Eli Somer. What is the 16-Point Maladaptive Daydreaming Scale? One significant milestone in the journey to wider acceptance is the development of a test that can accurately measure and diagnose MD as a distinct condition, with reliable symptoms and underlying mechanisms.ĭaydream researchers have made great strides in understanding the condition over the last few years, leading to the development of the 16-point maladaptive daydreaming scale (MDS-16). While it is yet to find a place as a widely-recognized and diagnosed condition, a growing body of research is emerging around MD and its causes, risk factors, and potential forms of treatment. Maladaptive Daydreaming (MD) is a newly discovered mental health condition characterized by immersion in vivid, extensive daydreams and leads to severe emotional and functional problems in daily life.
0 kommentar(er)
